

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/723,752

11/27/2000

Manuel Baca

P1093P1D1

CONFIRMATION NO. 6340

FORMALITIES LETTER

OC000000007228019

Attn: Steven X. Cui GENENTECH, INC. 1 DNA Way

South San Francisco, CA 94080-4990

Date Mailed: 12/26/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Patent Docket P1093P1D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RETAIN TE Application of

Manuel Baca et al.

Serial No.: 09/723,752

Filed: November 27, 2000

For:

ANTI-VEGF ANTIBODIES

Group Art Unit: 1614

Examiner: Not yet assigned

CONFIRMATION NO:

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

Mone Poltres

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

This is responsive to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures - Filing Date Granted dated December 26, 2001. Transmitted herewith are the following documents:

- 1. A paper copy of the Sequence Listing for USSN 08/908,469.
- 2. Certificate Re: Sequence Listing.
- Copy of Letter and Request To Use Computer-Readable Sequence Listing Under 37
 CFR §1.821(e) that was mailed to USPTO on June 26, 2001.
- Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures

Respectfully submitted,

GENENTECH, INC.

Date: February 12 2002

By: // . Steven X. Cui

Reg. No. 44,637

Telephone No. (650) 225-8674

09157

PATENT TRADEMARK OFFICE

#103668



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

But The Application of

Manuel Baca et al.

Serial No.: 09/723,752

Filed: November 27, 2000

For:

ANTI-VEGF ANTIBODIES

Group Art Unit: 1614

Examiner: Not yet assigned

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

Mona Beltran

CERTIFICATE RE: SEQUENCE LISTING

RESPONSE UNDER 37 CFR § 1.821(f) and (g)

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy. The information recorded in computer readable form (as submitted in application Serial No. 08/908,469, filed August 6, 1997,) is identical to the written sequence listing. I further state that this submission includes no new matter.

Respectfully submitted,

GENENTECH, INC.

Date: February / 2002

Steven X. Cui

Reg. No. 44,637

Telephone No. (650) 225-8674

PATENT TRADEMARK OFFICE

Patent Docket P1093P1D1

FEB 2 6 2002 H

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Manuel Baca et al.

Serial No.: 09/723,752

Filed: November 27, 2000

For:

ANTI-VEGF ANTIBODIES

Group Art Unit:

Examiner:

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

June 2%, 2001

Eileen Ly

Letter and REQUEST TO USE COMPUTER-READABLE SEQUENCE LISTING

UNDER 37 CFR \$1.821(e)

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Applicants respectfully request that the compliant computer-readable Sequence Listing filed in application Serial No. 08/908,469 be used as the computer-readable Sequence Listing for the present, above-identified application.

The paper copy of the Sequence Listing filed in the present application is identical to the computer-readable copy of the Sequence Listing filed in the application Serial No. 08/908,469.

Respectfully submitted,

GENENTECH, INC.

Date: June 26 2001

Steven X. Cui

Reg. No. 44,637

Telephone No. (650) 225-8674

09157

PATENT TRADEMARK OFFICE

#91819

